

**S1 Table. Included studies obtained using the inclusion and exclusion criteria of this review, separated into topics of focus.** The inclusion ID was designated, A: Pharmacokinetics/Pharmacodynamics, B: Drug-drug interactions, C: Metabolite analysis, D: Pharmacogenetics

Inclusion ID	Title
A/B	Abla, N., et al. (2017). "Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the schistosoma mansoni mouse model: Possible clinical implications." <i>Tropical Medicine and International Health</i> 22 (Supplement 1): 136-137.
B	Araujo, N., et al. (2008). "Association of oxamniquine praziquantel and clonazepam in experimental Schistosomiasis mansoni." <i>Memorias Do Instituto Oswaldo Cruz</i> 103(8): 781-785.
A	Bonate, P. L., et al. (2018). "Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale." <i>Journal of Pharmacokinetics and Pharmacodynamics</i> 45(5): 747-762.
A	Botros, S., et al. (2011). "Comparative efficacy and bioavailability of different praziquantel brands." <i>Experimental Parasitology</i> 127(2): 515-521.
B	Botros, S., et al. (2006). "Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different <i>S. mansoni</i> isolates." <i>Apmis</i> 114(7-8): 480-491.
A	Botros, S. S., et al. (2006). "Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring <i>Schistosoma mansoni</i> isolates of different drug susceptibilities." <i>Journal of Parasitology</i> 92(6): 1344-1349.
B	Botros, S. S., et al. (2010). "Praziquantel efficacy in mice infected with PZQ non-susceptible <i>S. mansoni</i> isolate treated with artemether: Parasitological, biochemical and immunohistochemical assessment." <i>Apmis</i> 118(9): 692-702.
A	Bustinduy, A. L., et al. (2016). "Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy." <i>Mbio</i> 7(4).
B	Campelo, Y. D. M., et al. (2017). "Synergistic effects of in vitro combinations of piplartine, epiisopiloturine and praziquantel against <i>Schistosoma mansoni</i> ." <i>Biomedicine &amp; Pharmacotherapy</i> 88: 488-499.
B	Ebeid, F. A. (1995). "Efficacy of a combination of metrifonate and praziquantel in the treatment of schistosoma-mansoni infection in albino mice." <i>Arzneimittel-Forschung/Drug Research</i> 45-1(4): 519-521.
A	Elguiniady, M. A., et al. (1994). "Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure." <i>American Journal of Tropical Medicine and Hygiene</i> 51(6): 809-818.
B	El-Lakkany, N. and M. Nosseir (2007). "Pharmacodynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoni." <i>Apmis</i> 115(3): 184-194.
B	El-Lakkany, N. M., et al. (2011). "Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult <i>Schistosoma mansoni</i> ." <i>Memorias Do Instituto Oswaldo Cruz</i> 106(7): 814-822.
A	Gotardo, M. A., et al. (2011). "Modulation of expression and activity of cytochrome P450s and alteration of praziquantel kinetics during murine schistosomiasis." <i>Memorias Do Instituto Oswaldo Cruz</i> 106(2): 212-219.
B	Hussein, A., et al. (2017). "Evaluation of the Anti-schistosomal Effects of Turmeric ( <i>Curcuma longa</i> ) Versus Praziquantel in <i>Schistosoma mansoni</i> Infected Mice." <i>Iranian Journal of Parasitology</i> 12(4): 587-596.
A/B	Jung, H., et al. (1997). "Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen." <i>Antimicrobial Agents and Chemotherapy</i> 41(6): 1256-1259.
B	Keiser, J., et al. (2011). "Interactions of mefloquine with praziquantel in the <i>Schistosoma mansoni</i> mouse model and in vitro." <i>Journal of Antimicrobial Chemotherapy</i> 66(8): 1791-1797.

B	Keiser, J., et al. (2010). "Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice." <i>Journal of Antimicrobial Chemotherapy</i> 65(9): 1991-1995.
A	Kokwaro, G. O. and G. Taylor (1990). "Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat." <i>Eur J Drug Metab Pharmacokinet</i> 15(3): 199-202.
A	Kovac, J., et al. (2018). "Pharmacokinetics of Praziquantel in Schistosoma mansoni- and Schistosoma haematobium-Infected School- and Preschool-Aged Children." <i>Antimicrobial Agents and Chemotherapy</i> 62(8).
A	Kovac, J., et al. (2018). "Evaluation of a novel micro-sampling device, Mitra (TM), in comparison to dried blood spots, for analysis of praziquantel in Schistosoma haematobium-infected children in rural Cote d'Ivoire." <i>Journal of Pharmaceutical and Biomedical Analysis</i> 151: 339-346.
A	Leopold, G., et al. (1978). "Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics." <i>European Journal of Clinical Pharmacology</i> 14(4): 281-291.
A/B	Lima, R. M., et al. (2011). "Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity." <i>British Journal of Clinical Pharmacology</i> 71(4): 528-535.
A/C	Lima, R. M., et al. (2009). "Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: Application to pharmacokinetics." <i>Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences</i> 877(27): 3083-3088.
A	Mandour, M. E., et al. (1990). "Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis." <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> 84(3): 389-393.
A/B	Masimirembwa, C. M., et al. (1993). "Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics of praziquantel in rats." <i>European Journal of Drug Metabolism and Pharmacokinetics</i> 18(3): 261-264.
A/B	Masimirembwa, C. M., et al. (1994). "The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans." <i>Biopharmaceutics &amp; Drug Disposition</i> 15(1): 33-43.
A	Meister, I., et al. (2014). "Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni." <i>Antimicrobial Agents and Chemotherapy</i> 58(9): 5466-5472.
A	Metwally, A., et al. (1995). "Impact of drug dosage and brand on bioavailability and efficacy of praziquantel." <i>Pharmacological Research</i> 31(1): 53-59.
A/B	Metwally, A., et al. (1995). "Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel." <i>Arzneimittel-Forschung/Drug Research</i> 45-1(4): 516-518.
A	Ofori-Adjei, D., et al. (1988). "Oral praziquantel kinetics in normal and Schistosoma haematobium-infected subjects." <i>Ther Drug Monit</i> 10(1): 45-49.
A	Pehrson, P. O., et al. (1983). "Treatment with praziquantel in a patient with schistosomiasis and chronic renal failure." <i>Trans R Soc Trop Med Hyg</i> 77(5): 687-688.
C	Schepmann, D. and G. Blaschke (2001). "Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel." <i>J Pharm Biomed Anal</i> 26(5-6): 791-799.
A	Tanaka, M., et al. (1989). "A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice." <i>American Journal of Tropical Medicine and Hygiene</i> 41(2): 198-203.
B	Utzinger, J., et al. (2001). "Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals." <i>Acta Tropica</i> 80(1): 9-18.
C	Wang, H. N., et al. (2014). "Metabolic profiling of praziquantel enantiomers." <i>Biochemical Pharmacology</i> 90(2): 166-178.
A	Zhang, D. L., et al. (2017). "A quantification method for determination of racemate praziquantel and R-enantiomer in rat plasma for comparison of their pharmacokinetics." <i>Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences</i> 1048: 64-69.